Polymyxins are often the only option to treat acquired multidrug-resistant Pseudomonas
aeruginosa. Polymyxin susceptibility in P. aeruginosa PAO1 is associated with the …

During investigation of susceptibility testing methods for polymyxins, 24 multidrug-resistant
clinical isolates of Pseudomonas aeruginosa were observed to have a distinct, reproducible …

Pseudomonas aeruginosa is a major causative agent of hospital-acquired infections and
infections in cystic fibrosis patients. Treatment of P. aeruginosa is complicated by the …

Pseudomonas aeruginosa can develop resistance to polymyxin as a consequence of
mutations in the PhoPQ regulatory system, mediated by covalent lipid A modification …

Pseudomonas aeruginosa can develop resistance to polymyxin and other cationic
antimicrobial peptides. Previous work has shown that mutations in the PmrAB and PhoPQ …

Polymyxin B and E (colistin) are the last resorts to treat multidrug-resistant Gram-negative
pathogens. Pseudomonas aeruginosa is intrinsically resistant to a variety of antibiotics. The …

Constitutive overexpression of the active efflux system MexXY/OprM is a major cause of
resistance to aminoglycosides, fluoroquinolones, and cefepime in clinical strains of …

Multidrug-resistant Pseudomonas aeruginosa presents a global medical challenge, and
polymyxins are a key last-resort therapeutic option. Unfortunately, polymyxin resistance in P …

Emergence of resistance to polymyxins in Pseudomonas aeruginosa is mainly due to
mutations in two-component systems that promote the addition of 4-amino-4-deoxy-l …

Multidrug resistance in Pseudomonas aeruginosa is increasingly becoming a threat for
human health. Indeed, some strains are resistant to almost all currently available antibiotics …